Volume Alert - MACK 9.27 Merrimack Pharmaceuticals Inc

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - MACK 9.27 Merrimack Pharmaceuticals Inc $MACK Hit a high today of 9.34 Closing the day 10:30 at 9.27 +0.33 +3.69% With a day low of 9.05 and a total volume of 895,523.

MACK Recent Posts: http://investorshangout.com/Merrimack-Pharmac...ACK-90045/

MACK Merrimack Pharmaceuticals Inc Recent Headline News

Insider Trading Alert - MACK, GWRE And CCOI Traded By Insiders
at The Street - 2 hrs 21 mins ago
Stocks with insider trader activity include MACK, GWRE and CCOI
MACK: 8.73 (-0.21), GWRE: 49.41 (-0.67), CCOI: 34.83 (-0.32)

Merrimack cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 9:14AM CST

MACK: 8.73 (-0.21)

Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer
GlobeNewswire - Wed Nov 19, 7:07AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI,'' Fast Track designation for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Fast Track is designed by the FDA to facilitate and expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.
MACK: 8.73 (-0.21), BAX: 72.45 (-0.13)

Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 8.73 (-0.21), INO: 9.43 (-0.43), ADXS: 2.90 (-0.01), GSK: 46.24 (-0.04), NKTR: 13.93 (-0.16), NVS: 95.69 (+0.11)

Cramer's Lightning Round - Mobileye Will Have A Good Quarter (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 17. Bullish Calls: Mobileye (NYSE: MBLY ) : "It has come down. I do feel it could have a good quarter. It has had a good run, there...
MACK: 8.73 (-0.21), DSX: 7.75 (-0.05), BIIB: 302.65 (-2.91), GE: 26.81 (-0.20), ALNY: 89.95 (unch), JCP: 7.20 (-0.12), MBLY: 46.51 (-0.82)

'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen
at The Street - Tue Nov 18, 5:00AM CST
Cramer's not recommending J.C. Penney, likes Alnylam Pharmaceuticals and thinks GE is getting better.
MACK: 8.73 (-0.21), DSX: 7.75 (-0.05), BIIB: 302.65 (-2.91), GE: 26.81 (-0.20), ALNY: 89.95 (unch), JCP: 7.20 (-0.12), MBLY: 46.51 (-0.82)

Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 43.28 (+0.86), BIIB: 302.65 (-2.91), GE: 26.81 (-0.20), NKE: 96.79 (+0.32), HAL: 48.43 (-0.11), TSN: 43.09 (+0.44), GSAT: 2.65 (+0.10), LULU: 45.32 (+0.52), AGN: 212.57 (-0.80), MACK: 8.73 (-0.21), WHR: 179.50 (+2.28), UA: 70.23 (+0.86), DSX: 7.75 (-0.05), ALNY: 89.95 (unch), MPC: 94.05 (+0.17), JCP: 7.20 (-0.12), SHW: 240.10 (-1.22), MBLY: 46.51 (-0.82), REGN: 415.62 (+2.40), BHI: 63.41 (-0.14)

Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors
GlobeNewswire - Mon Nov 17, 7:42AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Vivian S. Lee, Ph.D., M.D., M.B.A. to its Board of Directors. Lee currently serves as the Senior Vice President for Health Sciences at the University of Utah, Dean of the University's School of Medicine, and CEO of University of Utah Health Care, overseeing 15,000 employees.
MACK: 8.73 (-0.21)

Insider Trading Alert - TASR, SAVE And MACK Traded By Insiders
at The Street - Fri Nov 14, 11:49AM CST
Stocks with insider trader activity include TASR, SAVE and MACK
MACK: 8.73 (-0.21), SAVE: 75.92 (-0.41), TASR: 20.13 (unch)

Biothera Names Carey Anderson VP of Regulatory Affairs
Business Wire - Thu Nov 13, 8:30AM CST
Carey Anderson has joined Biothera as Vice President of Regulatory Affairs for its Pharmaceutical business.
MACK: 8.72 (-0.22), AMGN: 162.62 (+0.38)

Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 AACR-NCI-EORTC International Conference
GlobeNewswire - Thu Nov 13, 7:02AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present research on three of its therapeutic candidates at the 2014 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 18-21, 2014 in Barcelona, Spain. Data will be shared in four poster sessions. Presentations will include results from a clinical study using ferumoxytol as a magnetic resonance imaging agent and its ability to predict tumor response to MM-398, preclinical and clinical research on MM-151 and an initial preclinical study of MM-131, a novel bispecific antibody targeting the c-Met tumor signaling pathway.
MACK: 8.72 (-0.22)

Merrimack Pharma ups revenues 306% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:09AM CST

MACK: 8.72 (-0.22)

Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:29PM CST

MACK: 8.72 (-0.22)

Merrimack posts 3Q loss
Automated Insights - Mon Nov 10, 5:57PM CST
CAMBRIDGE, Mass. (AP) _ Merrimack Pharmaceuticals Inc. (MACK) on Monday reported a loss of $27.9 million, or 27 cents per share, in its third quarter.
MACK: 8.72 (-0.22)

Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its third quarter 2014 financial results. Merrimack will host a live conference call and webcast today, Monday, November 10 at 4:30 p.m., Eastern Time, to provide an update on Merrimack's progress as well as a summary of these results.
MACK: 8.72 (-0.22)

Merrimack Pharmaceuticals misses by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:09PM CST

MACK: 8.72 (-0.22)

What To Watch For: November 10-14
TipRanks - Seeking Alpha - Mon Nov 10, 10:36AM CST
Quarterly report releases are winding down as we reach mid-November. Stay ahead of Wall Street with this week’s top stories: Monday, November 10 Sotheby’s (NYSE: BID ): a worldwide broker of fine art and real estate ...
BID: 39.48 (-0.32), DHI: 24.77 (+0.14), MGNX: 24.18 (-0.40), KSS: 57.37 (+0.24), HK: 2.90 (+0.02), SEAS: 17.09 (+0.03), DDD: 36.01 (+0.64), SBH: 30.34 (+0.53), WMT: 85.16 (+1.37), M: 61.83 (+0.38), HP: 78.05 (+0.15), NTAP: 41.79 (-0.10), ENR: 123.85 (-0.67), MACK: 8.72 (-0.22), W: 22.20 (+0.12), FOSL: 107.70 (-0.32), AMAT: 22.62 (-0.06), JCP: 7.20 (-0.12), JWN: 73.66 (+0.14), PE: 16.74 (+0.23), DF: 16.93 (+0.01), VIAB: 73.06 (-0.69), CSCO: 26.50 (-0.09), ATW: 37.04 (+0.02)

Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.73 (-0.21), MNK: 85.19 (-3.61), INO: 9.44 (-0.42)

Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.73 (-0.21), MNK: 85.19 (-3.61), BAX: 72.45 (-0.13), LLY: 66.97 (-0.81)

Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.73 (-0.21), MNK: 85.19 (-3.61), DNDN: 0.13 (-0.02), ICPT: 155.65 (-6.85)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 114

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 99

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 0

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 52

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 305

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 319

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 24

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 13

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 225

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

UP Oncolytics Boosts Funding to Propel Brain Cancer Research

Updated Category News Views 171

UP Oncolytics Secures Significant Grant for Research Advancement UP Oncolytics, a pioneering biotechnology company specializing in neuro-oncology, is making headlines with its latest achievement in funding. This innovative company, a spin-out from a prominent research institution, has secured a matching grant to further its mission in developing oncolytic virus therapy...

Continue Reading
US Dollar Weakness Fuels Gold's Safe Haven Appeal Amid Trade Tensions

Updated Category News Views 269

US Dollar Weakness Benefits Gold Amid Trade Concerns The US dollar has been retreating against several major currencies, largely influenced by recent dovish comments from Fed Governor Waller. The anticipation of further developments in trade negotiations is another factor keeping investors on edge as they navigate these financial currents. Fed’s Influence on the Dollar...

Continue Reading
Tesla's Strategic Partnerships with Local Suppliers in China

Updated Category News Views 468

Tesla's Strategic Partnerships with Local Suppliers in China Tesla, Inc. (NASDAQ: TSLA) is taking significant steps to enhance its operational efficiency and local presence in the world's largest automotive market, China. Recently reported developments indicate that the iconic electric vehicle manufacturer has successfully established partnerships with over 400 local...

Continue Reading
Collect a Unique Piece of History: Trump Bobblehead Release

Updated Category News Views 324

Royal Bobbles Launches Limited Edition Bobblehead of President-Elect Trump Add an Iconic Piece of Presidential Inauguration History with a One-of-a-Kind President-Elect Donald J. Trump Bobblehead A Historic Collectible Honoring Strength and Patriotism Royal Bobbles, recognized as the original bobblehead maker, has made an exciting announcement. They are launching the 2025...

Continue Reading
Extant Capital's New $200 Million Investment Marks Growth Path

Updated Category News Views 219

Extant Capital Receives Significant Investment Boost Extant Capital, an alternative asset management firm, has made an exciting announcement regarding a substantial new investment. The firm has successfully secured a $200 million cornerstone investment from New Holland Capital, marking a pivotal moment in its growth journey. This strategic partnership is set to enhance...

Continue Reading